AstraZeneca plc has announced a new partnership with Amgen, under which the two companies will jointly commercialize TEZSPIRE in North America. As part of the agreement, Amgen will handle product sales in the United States, while AstraZeneca will record its share of U.S. profits as Collaboration Revenue. Outside the U.S., AstraZeneca will manage product sales, with Amgen recording profit share as Other/Collaboration revenue. This collaboration aims to enhance the companies' capabilities in addressing chronic respiratory and immune-mediated diseases, further solidifying AstraZeneca's leadership in respiratory care.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.